• Cell Therapy for Type of Epidermolysis Bullosa Advancing in Phase 1 Trial, Fibrocell Announces
  • Amicus Therapeutics Advances Development of Investigational Therapy SD-101 for EPB
  • Epidermolysis Bullosa Simplex Patients Need Better Pain Management Strategies, Small Study Finds
  • InMed and ATERA Partner to Test Cannabinoid Therapy Candidate INM-750 in Epidermolysis Bullosa
  • FDA Recommends Abeona’s EB-101 Gene Therapy to Advance Toward Phase 3 Trial
  • EMA Grants TXA127 Orphan Drug Status to Treat Epidermolysis Bullosa
  • Trial Evaluating Diacerein 1% Ointment as EBS Treatment Enrolls First Patient
  • FDA Grants Rare Pediatric Disease Designation to EB-101 as a Treatment for Blistering Skin Disorder